Fig. 1
Analysis of tumor growth inhibition following armed CRAd administration. Subcutaneous tumor xenografts were established on rear flank of female nude mice using SKOV3.ip1 cells. Tumor nodules were directly injected with 1010 vp (5 × 108 pfu/dose) of either CRAd-IL24, CRAd-ING4, CRAd-IL24/ING4 (5 × 109 vp of each armed CRAd), control CRAd or PBS alone on day 7 and injections were repeated weekly for 3 consecutive weeks. a Mean tumor volume of each group is shown through day 35 after tumor implantation. Each data point represents the cumulative mean of tumor volumes (mm3) in each group while vertical error bars depict standard deviations. b Kaplan-Meier curves of overall survival of animals treated with the indicated armed CRAd vectors, non-armed CRAd control, or PBS are shown. Data analysis provides no evidence that survival experience observed in mice treated with either CRAd-IL24, CRAd-ING4, or CRAd-IL24/ING4 (the indicated armed CRAd vectors) is significantly different from non-armed CRAd control (n.s.)